BiotechTube

AB-201 + Cyclophosphamide + Fludarabine

Phase 1/2Withdrawn
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Cancer

Conditions

Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Trial Timeline

Aug 1, 2023 → Apr 1, 2027

NCT ID
NCT05678205

About AB-201 + Cyclophosphamide + Fludarabine

AB-201 + Cyclophosphamide + Fludarabine is a phase 1/2 stage product being developed by Artiva Biotherapeutics for Breast Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05678205. Target conditions include Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05678205Phase 1/2Withdrawn

Competing Products

20 competing products in Breast Cancer

See all competitors
ProductCompanyStageHype Score
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
Abemaciclib + FulvestrantEli LillyPhase 2
52
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
41
gemcitabine + vinorelbineEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
33
AbemaciclibEli LillyPre-clinical
23
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
52
arzoxifeneEli LillyApproved
85
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
BBI-940 + FulvestrantBoundless BioPhase 1
25
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
77
pemetrexed + gemcitabineEli LillyPhase 2
52
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: SorafenibEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52

Other Products from Artiva Biotherapeutics

Allogeneic NK CellsPhase 2
44
AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2Phase 2
44
AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + BendamustinePhase 1/2
33
GCC2005 + Cyclophosphamide + FludarabinePhase 1
25
AB-101 + Cyclophosphamide + Fludarabine + Rituximab + ObinutuzumabPhase 1
25